Physician profile
Marion E Wright
NPI 1699986364
$55,267.89
in general payments reported to CMS, 2019-2025
27 companies · $294 in 2025
The $294 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,636 · 2020: $204 · 2021: $23K · 2022: $5,699 · 2023: $19K · 2024: $140 · 2025: $294.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $17K · Travel and Lodging: $1,775 · Food and Beverage: $765.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $16,650.00 |
| Travel and Lodging | $1,774.60 |
| Food and Beverage | $764.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $46,779.93 | 2021-2025 | Vraylar |
| Allergan, INC. | $6,917.51 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $255.69 | 2021-2025 | Uzedy |
| Otsuka America Pharmaceutical, INC. | $245.77 | 2019-2025 | Rexulti, Abilify Maintena, Nuedexta |
| Lundbeck LLC | $241.54 | 2019-2022 | |
| Tris Pharma INC | $199.09 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $77.09 | 2020-2022 | |
| Vanda Pharmaceuticals INC. | $57.37 | 2019-2022 | |
| Neos Therapeutics, Lp | $49.87 | 2019 | |
| Sunovion Pharmaceuticals INC. | $44.22 | 2019-2020 | |
| Ironshore Pharmaceuticals INC. | $42.07 | 2019 | |
| Neurocrine Biosciences, INC. | $41.24 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $35.26 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $32.89 | 2019 | |
| Avanir Pharmaceuticals, INC. | $30.06 | 2019 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arbor Pharmaceuticals, INC. | $30.06 | 2019 | |
| Indivior INC. | $27.43 | 2025 | Sublocade |
| Adlon Therapeutics L.P. | $25.10 | 2020 | |
| Jazz Pharmaceuticals INC. | $24.09 | 2019-2020 | |
| Eisai INC. | $16.58 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $16.46 | 2025 | Cobenfy |
| Neuronetics, INC. | $15.50 | 2020 | |
| Almatica Pharma LLC | $13.87 | 2022 | |
| Rhodes Pharmaceuticals L.P. | $13.86 | 2019 | |
| Alkermes, INC. | $13.10 | 2021 | |
| Shire North American Group INC | $11.36 | 2019 | |
| Vertical Pharmaceuticals, LLC | $10.88 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marion Wright listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.